Brighton Jones LLC Purchases 2,537 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Brighton Jones LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 244.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,575 shares of the medical research company’s stock after acquiring an additional 2,537 shares during the period. Brighton Jones LLC’s holdings in IQVIA were worth $703,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new position in IQVIA during the third quarter valued at $27,000. Park Place Capital Corp purchased a new position in IQVIA during the 3rd quarter valued at about $28,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. increased its stake in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 99 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.7 %

NYSE:IQV opened at $204.54 on Friday. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The business has a fifty day moving average price of $199.71 and a 200-day moving average price of $221.06. The firm has a market capitalization of $37.12 billion, a price-to-earnings ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on IQV shares. Redburn Atlantic initiated coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. The Goldman Sachs Group dropped their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, TD Cowen decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.